Janssen Biotech announced the initiation of an open enrollment process for the Doxil (doxorubicin HCl liposome injection) CARES Physician Access Program, starting May 11, 2012. The medication that will be allocated at this time was produced before Ben Venue Laboratories (BVL) suspended manufacturing last year.
Re-opening the enrollment was made possible because some physician allocation requests had changed which freed up products, and some patients no longer needed it or they were opted out of the program. Physicians who wish to enroll patients are now encouraged to download appropriate materials and forms.
Doxil is an anthracycline indicated in AIDS-related Kaposi’s sarcoma refractory to combination chemotherapy, ovarian cancer refractory to platinum-based chemotherapy, and multiple myeloma, in combination with Velcade (bortezomib injection; Millenium), in patients not previously treated with Velcade and who have received at least one prior therapy.
For more information call (866) 298-5774 or visit www.doxil.com.
This article originally appeared on MPR